Literature DB >> 17826998

Synthesis and screening of 3-substituted thioxanthen-9-one-10,10-dioxides.

Pedro M J Lory1, Maria E Estrella-Jimenez, Matthew J Shashack, Ganesh L Lokesh, Amarnath Natarajan, Scott R Gilbertson.   

Abstract

This manuscript describes methods appropriate for the parallel synthesis of libraries based on the tricyclic thioxanthen-9-one-10,10-dioxide scaffold. The novel compounds were synthesized from previously reported 3-chlorothioxanthen-9-one-10,10-dioxide and commercially available 3-carboxylic acid thioxanthen-9-one-10,10-dioxide. The library members were screened for activity in a fluorescence polarization assay for inhibitors of BRCT domains of breast cancer gene 1 and in cell-based secreted alkaline phosphatase reported replicon system for activity against hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17826998      PMCID: PMC2040121          DOI: 10.1016/j.bmcl.2007.07.103

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Selective inhibitors of monoamine oxidase. 4. SAR of tricyclic N-methylcarboxamides and congeners binding at the tricyclics' hydrophilic binding site.

Authors:  M Harfenist; D M Joseph; S C Spence; D P Mcgee; M D Reeves; H L White
Journal:  J Med Chem       Date:  1997-08-01       Impact factor: 7.446

2.  Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule.

Authors:  J P Stevenson; D DeMaria; D Reilly; J D Purvis; M A Graham; G Lockwood; M Drozd; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

3.  Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups.

Authors:  M Harfenist; D J Heuser; C T Joyner; J F Batchelor; H L White
Journal:  J Med Chem       Date:  1996-04-26       Impact factor: 7.446

4.  High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1.

Authors:  G L Lokesh; Aparna Rachamallu; G D Kishore Kumar; Amarnath Natarajan
Journal:  Anal Biochem       Date:  2006-02-03       Impact factor: 3.365

5.  Synthesis, cytotoxic activity, NMR study and stereochemical effects of some new pyrano[3,2-b]thioxanthen-6-ones and pyrano[2,3-c]thioxanthen-7-ones.

Authors:  I K Kostakis; N Pouli; P Marakos; E Mikros; A L Skaltsounis; S Leonce; G Atassi; P Renard
Journal:  Bioorg Med Chem       Date:  2001-11       Impact factor: 3.641

6.  Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.

Authors:  Nigel Bourne; Richard B Pyles; MinKyung Yi; Ronald L Veselenak; Melissa M Davis; Stanley M Lemon
Journal:  Antiviral Res       Date:  2005-08       Impact factor: 5.970

7.  Selective inhibitors of monoamine oxidase. 2. Arylamide SAR.

Authors:  M Harfenist; C T Joyner; P D Mize; H L White
Journal:  J Med Chem       Date:  1994-06-24       Impact factor: 7.446

8.  Phase I pharmacokinetic study of the novel antitumor agent SR233377.

Authors:  P M LoRusso; B J Foster; A Wozniak; L K Heilbrun; J I McCormick; P E Ruble; M A Graham; J Purvis; J Rake; M Drozd; G F Lockwood; T H Corbett
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

9.  Cancer chemopreventive effect of phenothiazines and related tri-heterocyclic analogues in the 12-O-tetradecanoylphorbol-13-acetate promoted Epstein-Barr virus early antigen activation and the mouse skin two-stage carcinogenesis models.

Authors:  Magnus A Azuine; Harukuni Tokuda; Junko Takayasu; Fumio Enjyo; Teruo Mukainaka; Takao Konoshima; Hoyoku Nishino; Govind J Kapadia
Journal:  Pharmacol Res       Date:  2004-02       Impact factor: 7.658

  9 in total
  1 in total

1.  Chiral Thioxanthones as Modulators of P-glycoprotein: Synthesis and Enantioselectivity Studies.

Authors:  Ana Lopes; Eva Martins; Renata Silva; Madalena M M Pinto; Fernando Remião; Emília Sousa; Carla Fernandes
Journal:  Molecules       Date:  2018-03-10       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.